Matrix metalloproteinase-9 as a potential tumor marker in breast cancer

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 32, Issue 2, 2013, Pages 115-129

  Nanda, Durga Prasad ^a   Sil, Hrishikesh ^a   Moulik, Shuvojit ^a   Biswas, Jaydip ^a   Mandal, Shyam Sundar ^a   Chatterjee, Amitava ^a  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

Author keywords

Breast cancer; ER; HER2; IDC; MMP 9; PR; TNM

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROGESTERONE RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CANCER THERAPY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 9; MENOPAUSE; MIDDLE AGED; NF-KAPPA B; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84884129654     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/JEnvironPatholToxicolOncol.2013008166     Document Type: Article

References (61)

1. Dano K, Behrendt N, Brunner N, Ellis V, Ploug M, Pyke C. The urokinase receptor: protein structure and the role in plasminogen activation and cancer invasion. Fibrinolysis. 1994;8:927-933.
2. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997;89:1260-1270.
3. Benaud CH, Dickson RB, Thompson EW. Roles of matrix metalloproteinases in mammary gland development and cancer. Breast Cancer Res Treat. 1998;50:97-116.
4. Yan S, Sameni M, Sloane BF. Cathepsin B and human tumor progression. Biol Chem. 1998;379:113-123.
5. Nelson A, Fingleton B, Rothenberg M. Matrix me-talloproteinase: biologic activity and clinical implications. J Clin Oncol. 2000;18:1135-1149.
6. Scorilas A, Talieri M, Ardavanis A, Courtis N, Dimitriadis E, Yotis J, Tsiapalis CM, Trangas T. Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: a new independent prognostic marker in primary breast cancer. Cancer Res. 2000;60:5427-5433.
7. Scorilas A, Black M, Talieri M, Diamandis E. Genomic organization, physical mapping and expression analysis of the human protein arginine methyltransferase 1 gene. Biochem Biophys Res Commun. 2000;278:349-359.
8. Magklara A, Scorilas A, Stephan C, Kristiansen GO, Hauptmann S, Jung K, Diamandis EP. Down-regulation of prostate specifc antigen (PSA) and human glandular kallikrein 2 (hK2) in malignant vs non-malignant prostatic tissue. Urology. 2000;56:527-532.
9. Yusef GM, Scorilas A, Diamandis EP. Genomic organization, mapping, tissue expression and hormonal regulation of trypsin-like serine protease (TLSP PRSS20), a new member of the human kal-likrein gene family. Genomics. 2000;63:88-96.
10. Yusef G, Scorilas A, Jung K, Aschworth L, Dia-mandis EP. The new human kallikrein gene KLK15 is up-regulated in prostate cancer. J Biol Chem. 2001;276:53-61.
11. Somiari SB, Somiari RI, Heckman CM, Olsen CH, Jordan RM, Russell SJ, Shriver CD. Circulating MMP2 and MMP9 in breast cancer-potential role in classifcation of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer. 2006;119:1403-1411.
12. Parsons SL, Watson SA, Brown PD, Collins HM, Steele RJC. Matrix metalloproteinases. Br J Surg. 1997;84:160-166.
13. Curran S, Murray GI. Matrix metalloprotein-ases in tumor invasion and metastasis. J Pathol. 1999;189:300-308.
14. Koblinski J, Abraham A, Sloane BF. Unraveling the role of proteases in cancer. Clin Chim Acta. 2000;291:113-135.
15. Nagase H, Woessner JF Jr. Matrix metalloprotei-nases. J Biol Chem. 1999;274:21491-21492.
16. Heppner JK, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metalloprotein-ase family members in breast cancer represents a tumor-induced host response. Am J Pathol. 1996;149:273-282.
17. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161-174.
18. Sternlicht MD, Werb Z. How matrix metallopro-teinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463-516.
19. Friedman R, Toth M, Pena D, Mobashery S. Activa-tion of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res. 1995;55:2548-2555.
20. Tryggvason K, Hoyhtya M, Pyke C. Type IV col-lagenase in invasive tumors. Br Cancer Res Treat. 1993;24:209-218.
21. Jones JL, Glynn P, Walker RA. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol. 1999;189:161-168.
22. Pellikainen JM, Ropponen KM, Kataja VV, Kello-koski JK. Expression of matrix metalloproteinase 2 and 9 in breast cancer with a special reference to activator protein, HER2, and prognosis. Clin Cancer Res. 2004:10:7621-7628.
23. Salmon DJ, Clark GM, Wrong SG. Human breast cancer: correlation of relapse and survival with amplifcation of HER-2/neu oncogene. Science. 1987;235:177-182.
24. Tan M, Yao J, Yu D. Over expression of the c erb2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res. 1997;57:1199-1205.
25. Belivean A, Mott JD, Lo A, Chen EI, Koller AA, Yaswen P, Muschler J, Bissell MJ. Raf induced MMP9 disrupts tissue architecture of human breast cells in three-dimensional culture and is necessary for tumor growth in vivo. Genes Dev. 2010;24:2800-2811.
26. Gorden DL, Frigleton B, Crawford HC, Jansen DE, Lepage M, Matrisian LM. Resident stromal cell derived MMP-9 promotes the growth of colorec-tal metastases in the liver microenvironment. Int J Cancer. 2007;121:495-500.
27. Kunigal S, Lakka SS, Joseph P, Estes N, Rao JS. Matrix metalloproteinase-9 inhibition downregu-lates radiation induced nuclear factor k-B activity leading to apoptosis in breast tumors. Clin Cancer Res. 2008;14:3617-3626.
28. Stankovic S, Konievie G, Gopuvic K, Jovic V, Inic M, Jurisic V. Activity of MMP-2 and MMP-9 in sera of breast cancer patients. Pathol Res Pract. 2010;266:241-247.
29. Wu Z, Wu Q, Yang J H, Wang HQ, Ding XD, Yang F, Xu XC. Prognostic signifcance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer. 2008;122:2050-2056.
30. Garbett EA, Reed MW, Brown NJ. Proteolysis in human breast and colorectal cancer. Br J Cancer. 1999:81:287-293.
31. Liu SC, Yang SF, Yeh KT, Yeh CM, Chiou HL, Lee CY, Chou MC, Hsieh YS. Relationship between the level of matrix metalloproteinase-2 and tumor size of breast cancer. Clin Chim Acta. 2006;371:92-96.
32. Shah FD, Shukla SN, Shah PM, Shukla HK, Pa-tel PS. Clinical signifcance of matrix metallo-proteinase 2 and 9 in breast cancer. Ind J Cancer. 2009;46:194-202.
33. Garbett EA, Reed MWR, Stephenson TJ, Brown NJ. Proteolysis in human breast cancer. J Clin Pathol Mol Pathol. 2000;53:99-106.
34. Remacle AG, Noël A, Duggan C, McDermott E, O'Higgins N, Foidart JM, Duffy MJ. Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer. 1998;77:926-931.
35. Brown PD, Bloxidge RE, Stuart NS, Gatter KC, Carmichael J. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst. 1993;85:574-578.
36. Giannelli G, Erriquez R, Fransvea E. Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients. Int J Cancer. 2004;109:782-785.
37. Quaranta M, Daniele A, Coviello M. MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer. Anti-cancer Res. 2007;27:3593-3600.
38. Davies B, Waxman J, Wasan H. Levels of matrix me-talloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res. 1993;53:5365-5369.
39. Soini Y, Hurskainen T, Höyhtyä M, Oikarinen A, Autio-Harmainen H. 72 KD and 92 KD type IV collagenase, type IV collagen, and laminin mRNAs in breast cancer: a study by in situ hybridization. J Histochem Cytochem. 1994;42:945-951.
40. Soini Y, Hurskainen T, Höyhtyä M, Oikarinen A, Autio-Harmainen H. 72 KD and 92 KD Type IV Collagenase, Type IV Collagen, and Laminin mRNAs in Breast Cancer: A Study by In Situ Hybridization. The J Histochcm Cytoehem. 1994;42: 945-951.
41. Jones JL, Glynn P, Rosemary Walker A. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol. 1999;189:161-168.
42. Scorilas A, Karameris A, Arnogiannaki N, Arda-vanis A, Bassilopoulos P, Trangas T, Talieri M. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br J Cancer. 2001;84:1488-1496.
43. Polette M, Gilbert N, Stas I, Nawrocki B, Nöel A, Remacle A, Stetler-Stevenson WG, Birembaut P, Foidart M. Gelatinase A expression and localization in human breast cancers. An in situ hybridization study and immunohistochemical detection using confocal microscopy. Virchows Arch. 1994;424:641-645.
44. Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, Taraboletti G, Giavazzi R. Matrix me-talloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res. 2003;63:5224-5249.
45. Huang S, Van Arsdall M, Tedjarati S, McCarty M, Wu W, Langley R, Fidler IJ. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst. 2002;94:1134-1142.
46. Mira E, Lacalle RA, Buesa JM, de Buitrago GG, Jiménez-Baranda S, Gómez-Moutón C, Martínez AC, Mañes S. Secreted MMP 9 promotes angio-genesis more effciently than constitutive active MMP9 bound to the tumor cell surface. J Cell Sci. 2004;117:1847-1857.
47. Fan SQ, Wei QY, Li MR, Zhang LQ, Liang QC. Expression and clinical signifcance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma [in Chinese]. Ai Zheng. 2003;22:968-973.
48. Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant me-tastases. Clin Cancer Res. 1997;3:1623-1628.
49. Mizumoto H, Saito T, Ashihara K, Nishimura M, Tanaka R, Kudo R. Acceleration of invasive, activity via matrix metalloproteinases by transfection of the estrogen, receptor-alpha gene in endometrial carcinoma cells. Int J Cancer. 2002;100:401-406.
50. Paquette B, Bisson M, Therriault H, Lemay R, Paré M, Banville P, Cantin AM. Activation of matrix me-talloproteinase-2 and -9 by 2- and 4-hydroxyestra-diol. J Steroid Biochem Mol Biol. 2003;87:65-73.
51. Thompson E W, Reich R, Shima TB. Differential regulation of growth and invasiveness of MCF-7 breast cancer cells by antiestrogens. Cancer Res. 1988;48:6764-6768.
52. Van den Brûle FA, Engel J, Stetler-Stevenson WG, Liu FT, Sobel ME, Castronovo V. Genes involved in tumor invasion and metastasis are differentially modulated by estradiol and progestin in human breast-cancer cells. Int J Cancer. 1992;52:653-657.
53. Patani MR, Jain J, Marya BH, Patel MB. Role of matrix metalloproteinase-2 in glioma patient spe-cifc in age, gender and menopausal status. J Globe Pharm Tech. 2011;3:38-44.
54. Kunigal S, Lakka SS, Joseph P, Estes N, Rao JS. Matrix metalloproteinase-9 inhibition down-regulates radiation-induced nuclear factor-kappa B activity leading to apoptosis in breast tumors. Clin Cancer Res. 2008;14:3617-3626.
55. Bhoopathi P, Chetty C, Kunigal S, Vanamala SK, Rao JS, Lakka SS. Blockade of tumor growth due to matrix metalloproteinase-9 inhibition is mediated by sequential activation of β1-integrin, ERK, and NF-kappaB. J Biol Chem. 2008;283:1545-1552.
56. Moulik S, Sen T, Dutta A, Banerji A, Ghosh C, Das S, Chatterjee A. Phosphatidylinositol 3-kinase and NF-κB involved in epidermal growth factor-induced matrix metalloproteinase-9 expression. J Cancer Mol. 2008;4:55-60.
57. Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, Chen B. EGFR gene amplifcation in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol. 2005;18:1027-1033.
58. Han SW, Ritzenthaler JD, Sitaraman SV, Roman J. Fibronectin increases matrix metalloproteinase 9 expression through activation of c-Fos via extracellular-regulated kinase and phosphatidylinositol 3-kinase pathways in human lung carcinoma cells. J Biol Chem. 2006;281:29614-29624.
59. Rolli M, Fransvea E, Pilch J, Saven A, Felding-Habermann B. Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:9482-9487.
60. Nakopoulou L, Tsirmpa I, Alexandrou P. MMP-2 protein in invasive breast cancer and the impact of MMP-2/TIMP-2 phenotype on overall survival. Breast Cancer Res Treat. 2003;77:145-155.
61. Maity G, Choudhury PR, Sen T, Ganguly KK, Sil H, Chatterjee A. Culture of human breast cancer cell line (MDA-MB-231) on fbronectin-coated surface induces pro-matrixmetalloproteinase-9 expression and activity. Tumour Biol. 2011;32:129-138.